Alana Hippensteele

Oncology pharmacists are increasingly shaping patient care.

Pharmacists optimize biosimilar and 505(b)(2) use through collaboration, education, and integration.

Two pharmacy leaders at UNC Health share how their distinct yet complementary leadership journeys and skill sets are driving innovation in clinical practice, education, and team development across the health system.

Selective reporting and underrepresentation distort biomedical evidence, affecting pharmacy practice

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses the expanding role of GLP-1 receptor agonists in holistic type 2 diabetes care, highlighting their cardio-renal-hepatic benefits, clinical access challenges, emerging investigational therapies, and practical strategies for individualized, guideline-based prescribing.

AI offers many benefits in health professions by efficiently handling time-consuming tasks crucial for patient care.

The National Comprehensive Cancer Network (NCCN) has updated its ovarian cancer guidelines version 3.2025 to recommend niraparib as maintenance therapy for patients with BRCA wild-type or homologous recombination (HR)–deficiency who did not receive bevacizumab during primary treatment.

The Phase 1 clinical trial for ARCT-2304, a self-amplifying mRNA vaccine, seeks to address pandemic influenza risk as H5N1 cases increase.

Laura R. Bobolts, PharmD, BCOP, shares actionable strategies for oncology pharmacists to navigate biosimilar and 505(b)(2) drug implementation, manage payer and formulary complexities, and optimize cost-effective care delivery across oncology service lines.

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, discusses how oncology pharmacists can lead value-based care efforts under the Enhanced Oncology Model (EOM) by improving care coordination, managing costs, aligning with performance metrics, and leveraging clinical data systems to enhance patient outcomes.